Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f
As we move forward in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines
As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines
2seventy bio is slashing 40% of its workforce to conserve cash as it tries to build momentum for its FDA-approved CAR-T therapy, while chief executive Nick Leschly is also
The FDA has approved Pfizer's BCMAxCD3 bispecific antibody Elrexfio as another off-the-shelf treatment option for people with multiple myeloma who have exhausted at least
Johnson & Johnson has become the first drugmaker to get FDA approval for a drug targeting GPRC5D, getting the nod for its bispecific antibody Talvey for a group of pat
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year